Evaluating cardiovascular risks in patients starting dialysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the relationship between levels of bone mineral markers and the progression of vascular calcification in patients who are beginning dialysis treatment for chronic kidney disease. Over a two-year follow-up period, researchers will measure plasma osteoprotegerin and fibroblast growth factor 23 levels, as well as vascular calcification scores. The goal is to better understand how these factors contribute to cardiovascular risks in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient who has signed the written consent form
* Patient with chronic renal failure starting dialysis therapy

Exclusion Criteria:

* Pregnancy
* Patient with chronic renal failure not yet on dialysis therapy

Where it's running

• Centre Hémodialyse du Lez
  Castelnau-le-Lez, France Recruiting
• Aider
  Montpellier, France Recruiting
• CHU Montpellier, Nephrology department
  Montpellier, France Recruiting
• CH Nimes, Nephrology department
  Nîmes, France Recruiting
• CH Perpignan, Nephrology department
  Perpignan, France Recruiting

Study contacts

• Principal investigator: Jean-Paul Cristol, Prof — CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE
• Study coordinator: Jean-Paul Cristol, Prof
• Email: jp-cristol@chu-montpellier.fr
• Phone: +33(0)4 67 33 83 15

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observational look at how Kremezin works in adults with advanced chronic kidney disease

  This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07930169

• Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China

  This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.

  Recruiting Phase 4 Novo Nordisk A/S · Fuyang, Anhui and 25 other locations · NCT07900438

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• NMR-based Risk Test and Digital Health Support for midlife adults in Eloisa

  This study tests whether an NMR metabolomics risk test can guide tailored digital health programs for midlife adults at risk of diabetes, heart disease, stroke, kidney disease, or fatty liver.

  Recruiting University of Eastern Finland · Savonlinna · NCT07820800

• Arterial stiffness in children and young people with CKD and hypertension

  This study will test whether arterial stiffness is higher in children and young people with chronic kidney disease and high blood pressure compared with their peers, using a one-time assessment and follow-up for those with high BP.

  Recruiting King's College London · London, Greater London · NCT07768865

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.